Clinical Trials for AZD9291

1 Open Trial

Trial TypeProtocol No. &
Open Date
A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumour Activity of Ascending Doses of AZD9291 in Patients with Advanced Non Small Cell Lung Cancer who have Progressed Following Prior Therapy with an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Agent (AURA)

Back to Find By Drug

You do not have JavaScript enabled. This site works better with JavaScript turned on.